IRCT20210612051550N1 IRCT 2021-06-20 Ahvaz University of Medical Sciences The effect of empagliflozin on reduction of cardiovascular complication after PCI Evaluation of the effect of empagliflozin administration on reduction of cardiovascular complication in diabetic patients after PCI 2021-07-23 anticipated 100 Complete https://irct.ir/trial/56886 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients will be assigned into two groups by simple randomization method. Allocation of patients to the study groups will be done by random-numbers table and using computer, and on this basis patients will be included in one of the treatment groups of empagliflozin or placebo after PCI procedure. The implementation of the random allocation sequence occurs without knowledge of which patient will receive which treatment, Blinding description: Intervention (receiving empagliflozin or placebo) and patient evaluation will be carried out by a physician who is blinded to treatment groups. Also patients and statistical analyzer will not know about patient grouping. 3 Type 2 diabetes mellitus. Intervention 1: Intervention group: The patients will received empagliflozin (Abidi Pharmaceutical Company, Iran; 10 mg or once daily) in addition to standard of care for 6 months after percutaneous coronary intervention (PCI). Intervention 2: Control group: The patients will received matching placebo, in addition to standard of care for 6 months after the PCI. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information.